Licensing status

Publication and contact information


Colon cancer

Retinoid X receptor-g (RXRG; RXRg)

In vitro and mouse studies suggest spironolactone or RXRg agonists could help treat colon cancer. In colon cancer cells, the generic mineralocorticoid receptor antagonist spironolactone increased levels of killer cell lectin-like receptor subfamily K
member 1
(KLRK1; CD314; NKG2D) ligands, which led to greater tumor cell lysis by NK cells than vehicle. In mouse xenograft models of colon cancer, spironolactone plus NK cells suppressed tumor growth and metastasis, whereas either treatment alone did not. In culture, genetic depletion of the mineralocorticoid receptor did not alter the effect of spironolactone on tumor cells, but siRNAs targeting RXRg did block the effects of spironolactone. Next steps include identifying RXRg agonists or RXRa (RXRA) antagonists.

SciBX 6(48); doi:10.1038/scibx.2013.1384
Published online Dec. 19, 2013

Provisional patent application filed; available for licensing

Leung, W.-H. et al. J. Exp. Med.; published online Nov. 4, 2013;
Contact: Wing Leung, St. Jude Children's Research Hospital, Memphis, Tenn.